These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 4561336)

  • 1. Clinical trial of nafoxidine, an oestrogen antagonist in advanced breast cancer.
    Eur J Cancer (1965); 1972 Aug; 8(4):387-9. PubMed ID: 4561336
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study.
    Heuson JC; Engelsman E; Blonk-Van Der Wijst J; Maass H; Drochmans A; Michel J; Nowakowski H; Gorins A
    Br Med J; 1975 Jun; 2(5973):711-3. PubMed ID: 1095121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases.
    Bloom HJ; Boesen E
    Br Med J; 1974 Apr; 2(5909):7-10. PubMed ID: 4362455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: Anti-oestrogens and breast cancer.
    Engelsman E; Korsten CB; Persijn JP; Cleton FJ
    Lancet; 1974 Jul; 2(7873):171-2. PubMed ID: 4135538
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-oestrogens and breast cancer.
    Terenius L
    Eur J Cancer (1965); 1971 Feb; 7(1):57-64. PubMed ID: 5576729
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trial of nafoxidine in adrenalectomized patients with advanced breast cancer.
    Jain J; Samal B; Singhakowinta A; Vaitkevicius VK
    Cancer; 1977 Nov; 40(5):2063-6. PubMed ID: 336179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study.
    Engelsman E; Heuson JC; Blonk Van Der Wijst J; Drochmans A; Maass H; Cheix F; Sobrinho LG; Nowakowski H
    Br Med J; 1975 Jun; 2(5973):714-5. PubMed ID: 1095122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter: Antioestrogens in treatment of breast cancer.
    Stoll BA
    Br Med J; 1974 May; 2(5916):447. PubMed ID: 4835320
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prolactin: radioimmunologic levels and changes under ethinyl estradiol and nafoxidine in advanced breast cancers in women].
    Gorins A; Netter A; L'Hermite M
    Ann Endocrinol (Paris); 1973; 34(5):601-2. PubMed ID: 4794619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogens in treatment of breast cancer.
    Tagnon HJ
    Cancer; 1977 Jun; 39(6 Suppl):2959-64. PubMed ID: 326387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oestrogen receptor in human breast cancer tissue and response to endocrine therapy.
    Engelsman E; Persijn JP; Korsten CB; Cleton FJ
    Br Med J; 1973 Jun; 2(5869):750-2. PubMed ID: 4352316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial of nafoxidine in advanced breast cancer.
    Steinbaum FL; De Jager RL; Krakoff IH
    Med Pediatr Oncol; 1978; 4(2):123-6. PubMed ID: 661750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafoxidine--an antiestrogen for the treatment of breast cancer.
    Legha SS; Slavik M; Carter SK
    Cancer; 1976 Oct; 38(4):1535-41. PubMed ID: 991075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic value of nafoxidine hydrochloride in the treatment of advanced carcinoma of the human breast.
    Sasaki GH; Leung BS; Fletcher WS
    Surg Gynecol Obstet; 1976 Apr; 142(4):560-4. PubMed ID: 1257870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of breast cancers with antiestrogens. Clinical study of nafoxidine].
    Metz R; Bey P
    Nouv Presse Med; 1977 Dec; 6(44):4145-6. PubMed ID: 600772
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapy with nafoxidine for patients suffering from postmenopausal ulcerated mammary cancer.
    Bumma C; Gino GC; Calciati A; La Grotta G; Gallo G; Falda M
    Panminerva Med; 1976; 18(3-4):137-41. PubMed ID: 1256902
    [No Abstract]   [Full Text] [Related]  

  • 17. Trioxifene mesylate (LY 133314): a new antiestrogen which inhibits growth hormone secretion in the rat.
    Arafah B; Manni A; Pearson OH
    Eur J Cancer (1965); 1980; Suppl 1():281-5. PubMed ID: 7032941
    [No Abstract]   [Full Text] [Related]  

  • 18. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
    Archer DF
    Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
    [No Abstract]   [Full Text] [Related]  

  • 19. [Further aspects of hormone therapy of metastatic breast cancer].
    Gorins A; Eskenazi F
    Sem Hop Ther; 1975 Jan; 51(1):41-3. PubMed ID: 1162373
    [No Abstract]   [Full Text] [Related]  

  • 20. Trioxifene mesylate in the treatment of advanced breast cancer.
    Lee RW; Buzdar AU; Blumenschein GR; Hortobagyi GN
    Cancer; 1986 Jan; 57(1):40-3. PubMed ID: 3940620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.